Cargando…
A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma
BACKGROUND: Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer. The prognostic signature could be reliable to stratify LUAD patients according to risk, which helps the management of the systematic treatments. In this study, a systematic and reliable immune signature was performed...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7060601/ https://www.ncbi.nlm.nih.gov/pubmed/32143735 http://dx.doi.org/10.1186/s12967-020-02286-z |